Tencent’s AI to Accelerate Parkinson’s Diagnosis


Chinese tech giant Tencent collaborated with London-based medical firm Medopad to utilize AI for early Parkinson’s diagnosis

Diagnosis of chronic disorders at early stage reduce the risk of unsuccessful treatment along with increasing life expectancy in terminal cases.  Parkinson’s is a degenerative affliction without any known cure. However, earlier diagnosis of the disease can allow patients to take necessary measures to lower down disease progression. The disease affects the central nervous system, predominately the motor system. It is characterized by symptoms such as shaking, rigidity, slowness of movement, and difficulty walking.

Tencent and Medopad utilized AI trained system on existing video footage of patients to detect concerned symptoms. The video analysis was conducted in collaboration with Kings College Hospital in London. The collaboration aims to reduce the time required for a motor function assessment to be performed from over 30 minutes to less than three. Therefore, accelerating diagnosis help people to opt for treatment earlier. Speaking to Forbes, Medopad CEO Dan Vahdat said, “Our partnership with Tencent comes from a shared vision to change the future of healthcare as we know it. In combining Medopad’s medical expertise and Tencent’s technical capabilities, we hope to provide the technology needed to support clinicians to predict preventable complications for people with Parkinson’s disease.”

Medopad is well known for using wearable for its healthcare solutions. Recent AI system will not require any physical sensors or devices to be worn, which reduces the amount of hardware required, in turn reducing cost and complexity for healthcare providers. Tencent and Medopad are demonstrated impact of AI on healthcare apart from cancer.



About Author

A passionate software developer with knack for jotting down error-free news pieces, Meg is an intellectual who loves technology. She has been compiling news pieces for Ace Newz in the technology genre.

Comments are closed.